SOS1 inhibitors and uses thereof
The present disclosure provides a compound of Formula (I) a pharmaceutically acceptable salt or a stereoisomer and their use in, e.g. treating a condition, disease or disorder in which the inhibition of the interaction of SOS 1 and a RAS-family protein or RAC1 is of therapeutic benefit, specifically in treating oncological diseases. This disclosure also features compositions containing the same as well as methods of using and making the same.
1 . A compound of formula I:
a pharmaceutically acceptable salt or a stereoisomer thereof, wherein:
ring A is 3-12 membered carbocyclyl, 3-12 membered heterocyclyl, 6-10 membered aryl, or 5-10 membered heteroaryl;
R 1 is hydrogen, halogen, C 1-6 alkyl, or C 3-6 cycloalkyl, wherein said C 1-6 alkyl or C 3-6 cycloalkyl represented by R 1 is optionally substituted by one to more groups selected from halogen and —OH;
V is N or CR 2 ; wherein
R 2 is hydrogen, halogen, —CN, C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, —OR 2a , —NR 2a R 2b , —C(O)R 2a , —C(O)OR 2a , —C(O)NR 2a R 2b , —SO 2 R 2a , —SO 2 NR 2a R 2b , —P(O)R 2a R 2b , —NR 2a C(O)R 2b , —NR 2a C(O)OR 2b , —NR 2a SO 2 R 2b , —NR 2a SO 2 NR 2b R 2c , 3-12 membered carbocyclyl, 3-12 membered heterocyclyl, 6-10 membered aryl, or 5-10 membered heteroaryl; wherein said C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, 3-12 membered carbocyclyl, 3-12 membered heterocyclyl, 6-10 membered aryl, or 5-10 membered heteroaryl represented by R 2 is optionally substituted by one or more R 2d , wherein
R 2a , R 2b , and R 2c are independently selected from the group consisting of hydrogen, C 1-6 alkyl, 3-12 membered carbocyclyl, 3-12 membered heterocyclyl, 6-10 membered aryl, and 5-10 membered heteroaryl; or R 2a and R 2b or R 2b and R 2c together with the N or P atom to which they are attached form 4-12 membered heterocyclyl or 5-10 membered heteroaryl; wherein said C 1-6 alkyl, carbocyclyl, heterocyclyl, aryl, or heteroaryl represented by R 2a , R 2b , or R 2c are optionally substituted with one or more R 2d ; wherein
R 2d , in each occurrence, is hydrogen, halogen, oxo, —CN, C 1-6 alkyl, C 1-6 haloalkyl, C 1-6 hydroxyalkyl, —OR 2e , —NR 2e R 2f , —C(O)R 2e , —C(O)OR 2e , —C(O)NR 2e R 2f , —SO 2 R 2e , —SO 2 NR 2e R 2f , —P(O)R 2e R 2f , —NR 2e C(O)R 2f , —NR 2e C(O)OR 2f , —NR 2e SO 2 R 2f , —NR 2e SO 2 NR 2f R 2g , 3-12 membered carbocyclyl, 3-12 membered heterocyclyl, 6-10 membered aryl, or 5-10 membered heteroaryl;
R 2e , R 2f , and R 2g are independently selected from the group consisting of hydrogen and C 1-6 alkyl;
X is N or CR 3 ;
R 3 is hydrogen, halogen, or C 1-3 alkyl;
R 4 is hydrogen or C 1-6 alkyl;
R 5 is hydrogen, C 1-6 alkyl, 3-6 membered monocyclic carbocyclyl, or 4-6 membered monocyclic heterocyclyl; wherein said C 1-6 alkyl, 3-6 membered monocyclic carbocyclyl, or 4-6 membered monocyclic heterocyclyl represented by R 5 is optionally substituted with one or more groups selected from halogen and —OH;
R 6 is hydrogen, —OH, halogen, —CN, oxo, C 1-6 alkyl, C 1-6 alkoxy, —SO 2 R 6a , —SO 2 NR 6a R 6b , —P(O)R 6a R 6b , —C(O)NR 6a R 6b , —NR 6a C(O)R 6a , —NR 6a C(O)NR 6a R 6b , —(CH 2 ) s NR 6a R 6b , —O(CH 2 ) t NR 6a R 6b , 3-12 membered carbocyclyl, 3-12 membered heterocyclyl, 6-10 membered aryl, 5-10 membered heteroaryl; wherein said C 1-6 alkyl, C 1-6 alkoxy, 3-12 membered carbocyclyl, 3-12 membered heterocyclyl, 6-10 membered aryl, or 5-10 membered heteroaryl represented by R 6 is optionally substituted by one to more R 6c ; wherein
R 6a and R 6b are independently hydrogen or C 1-6 alkyl, or R 6a and R 6b together with the N or P atom to which they are attached form 4-7 membered heterocyclyl;
s is an integral from 0 to 3;
t is an integral from 2 to 4;
R 6c , in each occurrence, is hydrogen, —OH, halogen, —CN, oxo, C 1-6 alkyl, C 1-6 alkoxy, C 3-6 cycloalkyl, —NR 6a R 6b , —SO 2 R 6a , —SO 2 NR 6a R 6b , —C(O)NR 6a R 6b , —P(O)R 6a R 6b , —NR 6a C(O)R 6a , —NR 6a C(O)NR 6a R 6b , —(CH 2 ) s NR 6a R 6b , or
—O(CH 2 ) t NR 6a R 6b ; wherein said C 1-6 alkyl or C 3-6 cycloalkyl represented by R 6c is optionally substituted with one to more groups selected from halogen, —OH and —NR 6a R 6b ;
R 7 and R 8 are independently hydrogen, C 1-6 alkyl, C 3-6 alkenyl, C 3-6 alkynyl, C 2-6 alkoxy, 3-12 membered carbocyclyl, 3-12 membered heterocyclyl, 6-10 membered aryl, or 5-10 membered heteroaryl; wherein said C 1-6 alkyl, C 3-6 alkenyl, C 3-6 alkynyl, C 2-6 alkoxy, 3-12 membered carbocyclyl, 3-12 membered heterocyclyl, 6-10 membered aryl, or 5-10 membered heteroaryl represented by R 7 or R 8 is optionally substituted by one or more R 7a ; or
R 7 and R 8 together with the N atom to which they are attached form 4-12 membered heterocyclyl or 5-10 membered heteroaryl; wherein said 4-12 membered heterocyclyl or 5-10 membered heteroaryl is optionally substituted with one or more R 7 b;
R 7a is hydrogen, halogen, —CN, C 1-6 alkyl, —OR 7c , —NR 7c R 7d , —C(O)R 7c , —C(O)OR 7c , —C(O)NR 7c R 7d , —SO 2 R 7c , —P(O)R 7c R 7d , —SO 2 NR 7c R 7d , —NR 7c C(O)R 7d , —NR 7c C(O)OR 7d , —NR 7c SO 2 R 7d , —NR 7c SO 2 NR 7d R 7e , 3-12 membered carbocyclyl, 3-12 membered heterocyclyl, 6-10 membered aryl, or 5-10 membered heteroaryl, wherein said C 1-6 alkyl, 3-12 membered carbocyclyl, 3-12 membered heterocyclyl, 6-10 membered aryl, or 5-10 membered heteroaryl represented by R 7 ª is optionally substituted by one or more R 7f ;
R 7b is hydrogen, halogen, —CN, oxo, C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 1-6 alkoxy, —OR 7c , —NR 7c R 7d , —C(O)R 7c , —C(O)OR 7c , —C(O)NR 7c R 7d , —SO 2 R 7c , —P(O)R 7c R 7d , —SO 2 NR 7c R 7d , —NR 7c C(O)R 7d , —NR 7c C(O)OR 7d , —NR 7c SO 2 R 7d , —NR 7c SO 2 NR 7d R 7e , 3-12 membered carbocyclyl, 3-12 membered heterocyclyl, 6-10 membered aryl, or 5-10 membered heteroaryl, wherein C 1-6 alkyl, C 2-6 alkenyl, C 2-6 alkynyl, C 1-6 alkoxy, 3-12 membered carbocyclyl, 3-12 membered heterocyclyl, or 5-10 membered heteroaryl represented by R 7b is optionally substituted by one or more R 7f ;
R 7c , R 7d , and R 7e are independently selected from the group consisting of hydrogen, C 1-6 alkyl, 3-12 membered carbocyclyl, 4-12 membered heterocyclyl, 6-10 membered aryl, and 5-10 membered heteroaryl; or R 7c and R 7d together with the N or P atom to which they are attached form 4-12 membered heterocyclyl or 5-10 membered heteroaryl; wherein said C 1-6 alkyl, carbocyclyl, heterocyclyl, aryl, or heteroaryl represented by R 7c , R 7d , or R 7e is optionally substituted with one or more R 7f ;
R 7f , in each occurrence, is hydrogen, halogen, —CN, or —OH; and
n is 0, 1, 2, or 3;
wherein said heterocyclyl comprises 1-4 heteroatoms selected from O, N, and S; and said heteroaryl comprises 1-4 heteroatoms selected from O, N, and S.
2 . The compound of claim 1 or a pharmaceutically acceptable salt or a stereoisomer thereof, wherein the compound is represented by Formula II:
3 . The compound of claim 2 , or a pharmaceutically acceptable salt or a stereoisomer thereof, wherein
ring A is 3-10 membered carbocyclyl, 4-10 membered heterocyclyl, 6-10 membered aryl, or 5-10 membered heteroaryl;
R 1 is hydrogen, C 1-4 alkyl, or C 3-6 cycloalkyl;
R 2 is hydrogen, halogen, —CN, C 1-4 alkyl, C 2-4 alkenyl, C 2-4 alkynyl, —OR 2a , —NR 2a R 2b , —C(O)R 2a , —C(O)OR 2a , —C(O)NR 2a R 2b , —NR 2a C(O)R 2b , —NR 2a C(O)OR 2b , 3-6 membered monocyclic carbocyclyl, 3-6 membered monocyclic heterocyclyl, 6-10 membered aryl, or 5-10 membered heteroaryl; wherein said C 1-4 alkyl, C 2-4 alkenyl, C 2-4 alkynyl, 3-6 membered monocyclic carbocyclyl, 3-6 membered monocyclic heterocyclyl, 6-10 membered aryl, or 5-10 membered heteroaryl represented by R 2 is optionally substituted by one to three R 2d ; wherein
R 2a and R 2b are independently selected from the group consisting of hydrogen, C 1-6 alkyl, C 1-6 haloalkyl, or C 1-6 hydroxyalkyl; or R 2a and R 2b together with the N atom to which they are attached form 4-12 membered heterocyclyl or 5-10 membered heteroaryl;
R 2d , in each occurrence, is hydrogen, halogen, oxo, —CN, C 1-6 alkyl, C 1-6 haloalkyl, C 1-6 hydroxyalkyl, —OR 2e , —NR 2e R 2f , —SO 2 R 2e , —P(O)R 2e R 2f , COOR 2e , CONR 2e R 2f , 3-6 membered monocyclic carbocyclyl, 3-6 membered monocyclic heterocyclyl, 6-10 membered aryl, or 5-10 membered heteroaryl;
R 2e and R 2f are independently selected from the group consisting of hydrogen and C 1-6 alkyl;
R 5 is hydrogen, C 1-4 alkyl, 3-5 membered monocyclic carbocyclyl, or 4-5 membered monocyclic heterocyclyl;
R 6 is hydrogen, —OH, halogen, —CN, oxo, C 1-6 alkyl, —(CH 2 ) s NR 6a R 6b , 3-6 membered monocyclic carbocyclyl, 3-6 membered monocyclic heterocyclyl, 6-10 membered aryl, 5-10 membered heteroaryl; wherein said C 1-6 alkyl, 3-6 membered monocyclic carbocyclyl, 3-6 membered monocyclic heterocyclyl, 6-10 membered aryl, or 5-10 membered heteroaryl represented by R 6 is optionally substituted by one to more R 6c ; wherein
R 6a and R 6b are independently hydrogen or C 1-4 alkyl;
s is an integral from 0 to 2;
R 6c , in each occurrence, is hydrogen, —OH, halogen, —CN, oxo, C 1-6 alkyl, —NR 6a R 6b , or —(CH 2 )NR 6a R 6b ; wherein said C 1-6 alkyl represented by R 6c is optionally substituted with one to more groups selected from halogen and —OH;
R 7 and R 8 are independently hydrogen, C 1-4 alkyl, C 3-4 alkenyl, C 3-4 alkynyl, C 2-4 alkoxy, 3-6 membered monocyclic carbocyclyl, 3-6 membered monocyclic heterocyclyl, 6-10 membered aryl, or 5-10 membered heteroaryl; wherein said C 1-4 alkyl, C 3-4 alkenyl, C 3-4 alkynyl, C 2-4 alkoxy, 3-6 membered monocyclic carbocyclyl, 3-6 membered monocyclic heterocyclyl, 6-10 membered aryl, or 5-10 membered heteroaryl represented by R 7 or R 8 is optionally substituted by one or more R 7a ; or
R 7 and R 8 together with the N atom to which they are attached form 4-12 membered heterocyclyl or 5-10 membered heteroaryl; wherein said 4-12 membered heterocyclyl or 5-10 membered heteroaryl is optionally substituted with one to three R 7b ;
R 7a is hydrogen, halogen, —CN, C 1-6 alkyl, —OR 7c , or —NR 7c R 7d ,
R 7b is hydrogen, halogen, —CN, oxo, C 1-6 alkyl, C 1-6 alkoxy, —OR 7c , —NR 7c R 7d , —C(O)R 7c , —C(O)OR 7c , —SO 2 R 7c , or 5-10 membered heteroaryl, wherein C 1-6 alkyl, C 1-6 alkoxy, or 5-10 membered heteroaryl represented by R 7b is optionally substituted by one or more R 7f ;
R 7c and R 7d are independently selected from the group consisting of hydrogen, C 1-4 alkyl, 3-6 membered monocyclic carbocyclyl, 4-8 membered heterocyclyl, 6-10 membered aryl, and 5-10 membered heteroaryl; or R 7c and R 7d together with the N atom to which they are attached form 4-8 membered heterocyclyl or 5-10 membered heteroaryl; wherein said C 1-4 alkyl, 3-6 membered monocyclic carbocyclyl, 4-8 membered heterocyclyl, 6-10 membered aryl, or 5-10 membered heteroaryl represented by R 7c or R 7d is optionally substituted with one to three R 7f ; and
R 7f , in each occurrence, is hydrogen, halogen, —CN, or —OH.
4 . The compound of claim 3 or a pharmaceutically acceptable salt or a stereoisomer thereof, wherein
R 2 is hydrogen, halogen, —CN, C 1-4 alkyl, C 2-4 alkenyl, C 2-4 alkynyl, 3-6 membered monocyclic carbocyclyl, 3-6 membered monocyclic heterocyclyl, 6-10 membered aryl, or 5-10 membered heteroaryl; wherein said C 1-4 alkyl, C 2-4 alkenyl, C 2-4 alkynyl, 3-6 membered monocyclic carbocyclyl, 3-6 membered monocyclic heterocyclyl, 6-10 membered aryl, or 5-10 membered heteroaryl represented by R 2 is optionally substituted by one to three R 2d ; wherein
R 2d , in each occurrence, is hydrogen, halogen, oxo, —CN, C 1-6 alkyl, C 1-6 haloalkyl, C 1-6 hydroxyalkyl, —OR 2e , —NR 2e R 2f , —SO 2 R 2e , —P(O)R 2e R 2f , COOR 2e , CONR 2e R 2f , 3-6 membered monocyclic carbocyclyl, 3-6 membered monocyclic heterocyclyl, 6-10 membered aryl, or 5-10 membered heteroaryl; and
R 2e and R 2f are independently selected from the group consisting of hydrogen and C 1-6 alkyl.
5 . The compound of claim 4 or a pharmaceutically acceptable salt or a stereoisomer thereof, wherein
R 7 and R 8 are independently hydrogen, C 1-4 alkyl, C 3-4 alkenyl, C 3-4 alkynyl; wherein said C 1-4 alkyl, C 3-4 alkenyl, C 3-4 alkynyl represented by R 7 or R 8 is optionally substituted by one or more R 7a ; or
R 7 and R 8 together with the N atom to which they are attached form 4-12 membered heterocyclyl or 5 membered heteroaryl, each of which is optionally substituted with one to three R 7b ;
R 7a is hydrogen, halogen, —CN, C 1-6 alkyl, —OR 7c , or —NR 7c R 7d ;
R 7b is hydrogen, halogen, —CN, oxo, —OH, C 1-6 alkyl, C 1-6 alkoxy, —NR 7c R 7d , —C(O)R 7c , —C(O)OR 7c , —SO 2 R 7c , or 5-10 membered heteroaryl, wherein C 1-6 alkyl, C 1-6 alkoxy, or 5-10 membered heteroaryl represented by R 7b is optionally substituted by one or more R 7f ;
R 7c and R 7d are independently selected from the group consisting of hydrogen, C 1-4 alkyl, 3-6 membered monocyclic carbocyclyl, 4-8 membered heterocyclyl, 6-10 membered aryl, and 5-10 membered heteroaryl; or R 7c and R 7d together with the N atom to which they are attached form 4-8 membered heterocyclyl or 5-10 membered heteroaryl; wherein said C 1-4 alkyl, 3-6 membered monocyclic carbocyclyl, 4-8 membered heterocyclyl, 6-10 membered aryl, or 5-10 membered heteroaryl represented by R 7c or R 7d is optionally substituted with one to three R 7f ; and
R 7f , in each occurrence, is hydrogen, halogen, —CN, or −OH.
6 . The compound of claim 5 or a pharmaceutically acceptable salt or a stereoisomer thereof, wherein
i) ring A is 3-6 membered monocyclic cycloalkyl, 4-6 membered monocyclic heterocyclyl, phenyl, or 5-10 membered heteroaryl;
R 6 is hydrogen, —OH, halogen, —CN, C 1-6 alkyl, or —(CH 2 ) s NR 6a R 6b ; wherein said C 1-6 alkyl represented by R 6 is optionally substituted with one to more groups selected from halogen and —OH;
R 6a and R 6b are independently hydrogen or C 1-4 alkyl; and
s is 0, or 1; or
ii) ring A is cyclopropyl, phenyl, thiophene, or indole.
7 . The compound of claim 1 or a pharmaceutically acceptable salt or stereoisomer thereof, wherein the compound is represented by Formula (III-A) or (III-B):
8 . The compound of claim 7 or a pharmaceutically acceptable salt or a stereoisomer thereof, wherein R 6 is hydrogen, halogen, C 1-4 alkyl, or —(CH 2 )NR 6a R 6b ; wherein said C 1-4 alkyl represented by R 6 is optionally substituted with one to more groups selected from halogen and —OH; and R 6a and R 6b are independently hydrogen or C 1-4 alkyl.
9 . The compound of claim 8 or a pharmaceutically acceptable salt or a stereoisomer thereof, wherein R 5 is hydrogen, methyl, or ethyl.
10 . The compound of claim 9 or a pharmaceutically acceptable salt or a stereoisomer thereof, wherein
i) R 2 is hydrogen, halogen, —CN, C 1-4 alkyl, C 2-4 alkenyl, 3-6 membered monocyclic cycloalkyl, 5-6 membered monocyclic heterocyclyl, phenyl, or 5-10 membered heteroaryl; wherein said C 1-4 alkyl, 3-6 membered monocyclic cycloalkyl, 5-6 membered monocyclic heterocyclyl, phenyl, or 5-10 membered heteroaryl represented by R 2 is optionally substituted by one to three R 2d ;
R 2d , in each occurrence, is hydrogen, halogen, oxo, —CN, C 1-6 alkyl, C 1-6 haloalkyl, C 1-6 hydroxyalkyl, —OR 2e , —NR 2e R 2f , —SO 2 R 2e , —P(O)R 2e R 2f , COOR 2e , CONR 2e R 2f , 3-6 membered monocyclic carbocyclyl, 3-6 membered monocyclic heterocyclyl, phenyl, or 5-10 membered heteroaryl; and
R 2e and R 2f are independently selected from the group consisting of hydrogen and C 1-6 alkyl;
ii) R 2 is phenyl or 5-10 membered heteroaryl; wherein said phenyl or 5-10 membered heteroaryl is optionally substituted by one to three R 2d ;
R 2d , in each occurrence, is hydrogen, halogen, —CN, C 1-6 alkyl, C 1-6 haloalkyl, C 1-6 hydroxyalkyl, —OR 2e , —NR 2e R 2f , —SO 2 R 2e , —P(O)R 2e R 2f , COOR 2e , CONR 2e R 2f , 3-6 membered monocyclic carbocyclyl, 3-6 membered monocyclic heterocyclyl, phenyl, or 5-10 membered heteroaryl; and
R 2e and R 2f are independently selected from the group consisting of hydrogen and C 1-6 alkyl;
iii) R 2 is phenyl, pyridyl, pyrimidyl, imidazolyl, pyrazolyl, imidazo[1,2-a]pyrimidine, imidazo[1,2-a]pyridine, or triazolo[4,3-a]pyridine, each of which is optionally substituted by one to three R 2d ; wherein R 2d is selected from the group consisting of hydrogen, halogen, —CN, —CH 3 , —CF 3 , —NH 2 , —S(O) 2 Me, —OCH 3 , COOH, CONH 2 , COOMe, —P(O)(CH 3 ) 2 , —CH 2 CH 2 OH, and —CH 2 CHF 2 ; or
iv) R 2 is phenyl or pyridyl, each of which is optionally substituted by one to three R 2d ; wherein R 2d is selected from the group consisting of hydrogen, halogen, —CN, —CH 3 , —CF 3 , —NH 2 , —S(O) 2 Me, —OCH 3 , COOH, CONH 2 , COOMe, —P(O)(CH 3 ) 2 , —CH 2 CH 2 OH, and —CH 2 CHF 2 .
11 . The compound of claim 10 or a pharmaceutically acceptable salt or a stereoisomer thereof, wherein
i) R 7 and R 8 together with the N atom to which they are attached form 5-10 membered heterocyclyl or 5 membered heteroaryl, each of which is optionally substituted with one to three groups selected from halogen, —CN, oxo, —OH, C 1-6 alkyl, C 1-6 alkoxy, —C(O)R 7c , —C(O)OR 7c , and pyridinyl optionally substituted with CN;
R 7c is independently selected from the group consisting of hydrogen, C 1-4 alkyl optionally substituted with —CN or —OH; or
ii) R 7 and R 8 are independently hydrogen or C 1-4 alkyl.
12 . The compound of claim 11 , or a pharmaceutically acceptable salt or a stereoisomer thereof, wherein R 2 is selected from the group consisting of
wherein R 2d is selected from the group consisting of hydrogen, halogen, —CN, —CH 3 , —CF 3 , —NH 2 , —S(O) 2 Me, —OCH 3 , COOH, CONH 2 , COOMe, —P(O)(CH 3 ) 2 , —CH 2 CH 2 OH, and —CH 2 CHF 2 .
13 . The compound of claim 12 or a pharmaceutically acceptable salt or a stereoisomer thereof, wherein R 7 and R 8 together with the atom to which they are attached form a heterocyclyl selected from the group consisting of
each of which is optionally substituted with one to three groups selected from —F, —CN, oxo, —OH, methyl, isopropyl, methoxy, —C(O)R 7c , —C(O)OR 7c , and pyridinyl optionally substituted with CN.
14 . A compound selected from the group consisting of
ID
Structure
Example 1
Example 2
Example 3
Example 4
Example 5
Example 6
Example 7
Example 8
Example 9
Example 10
Example 11
Example 12
Example 13
Example 14
Example 15
Example 16
Example 17
Example 18
Example 19
Example 20
Example 21
Example 22
Example 23
Example 24
Example 25
Example 26
Example 27
Example 28
Example 29
Example 30
Example 31
Example 32
Example 33
Example 34
Example 35
Example 36
Example 37
Example 38
Example 39
Example 40
Example 41
Example 42
Example 43
Example 44
Example 45
Example 46
Example 47
Example 48
Example 49
Example 50
Example 51
Example 52
Example 53
Example 54
Example 55
Example 56
Example 57
Example 58
Example 59
Example 60
Example 61
Example 62
Example 63
Example 64
Example 65
Example 66
Example 67
Example 68
Example 69
Example 70
Example 71
Example 72
Example 73
Example 74
Example 75
Example 76
Example 77
Example 78
Example 79
Example 80
Example 81
Example 82
Example 83
Example 84
Example 85
Example 86
Example 87
or a pharmaceutically acceptable salt or a stereoisomer thereof.
15 . A pharmaceutical composition comprising the compound of claim 1 , or a pharmaceutically acceptable salt or a stereoisomer thereof, and a pharmaceutically acceptable carrier or excipient.
16 . A method of treating a subject with a disease and/or a condition wherein the inhibition of the interaction of SOS1 and a RAS-family protein or RAC1 is of therapeutic benefit comprising administering to the subject a therapeutically effective amount of the compound of claim 1 or a pharmaceutically acceptable salt or a stereoisomer thereof.
17 . A method of treating a subject with cancer comprising administering to the subject a therapeutically effective amount of the compound of claim 1 or a pharmaceutically acceptable salt or a stereoisomer thereof; wherein the cancer selected from the group consisting of pancreatic cancer, lung cancer, colorectal cancer, cholangiocarcinoma, multiple myeloma, melanoma, uterine cancer, endometrial cancer, thyroid cancer, acute myeloid leukaemia, bladder cancer, urothelial cancer, gastric cancer, cervical cancer, head and neck squamous cell carcinoma, diffuse large B cell lymphoma, oesophageal cancer, chronic lymphocytic leukemia, hepatocellular cancer, breast cancer, ovarian cancer, prostate cancer, glioblastoma, renal cancer and sarcoma.
18 . The method of claim 17 , wherein the compound or a pharmaceutically acceptable salt or a stereoisomer thereof is administered in combination with a therapeutically effective amount of at least one other pharmacologically active substance.
19 . The method of claim 18 , wherein the at least one other pharmacologically active substance is an inhibitor of MEK and/or of mutants thereof.
20 . A compound, a pharmaceutically acceptable salt, or a stereoisomer thereof, wherein the compound is